SCOPUS 정보 검색 플랫폼

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 11, 2015, Pages 7007-7010

Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection

(6) Gallagher, Jason C a Reilly, Joseph P b Navalkele, Bhagyashri c Downham, Gemma b Haynes, Kevin d Trivedi, Manish b

a TEMPLE UNIVERSITY (United States)

b AtlantiCare (United States)

c DETROIT MEDICAL CENTER (United States)

d HEALTHCORE INC (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; FIDAXOMICIN; VANCOMYCIN; AMINOGLYCOSIDE;

AGED; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COST CONTROL; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG COST; HOSPITAL COST; HOSPITAL READMISSION; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; REIMBURSEMENT; RETROSPECTIVE STUDY; TREATMENT DURATION; CLOSTRIDIUM INFECTIONS; DRUG EFFECTS; ECONOMICS; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE;

AMINOGLYCOSIDES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; RETROSPECTIVE STUDIES; VANCOMYCIN;

EID: 84946223764 PISSN: 00664804 EISSN: 10986596 Source Type: Journal
DOI: 10.1128/AAC.00939-15 Document Type: Article

Times cited : (43)

References (11)

1
- 84923775846
- Burden of clostridium difficile infection in the United States
- Lessa FC, Mu Y, Bamberg W.M., Beldavs ZG, Dumyati GK, Dunn JR, Farley M.M., Holzbauer SM, Meek JI, Phipps EC, Wilson L.E., Winston LG, Cohen JA, Limbago BM, Fridkin S.K., Gerding DN, McDonald LC. 2015. Burden of Clostridium difficile infection in the United States. N Engl J Med 372:825-834. http://dx.doi.org/10.1056/NEJMoa1408913.
- (2015) N Engl J Med , vol.372 , pp. 825-834
- Lessa, F.C.¹ Mu, Y.² Bamberg, W.M.³ Beldavs, Z.G.⁴ Dumyati, G.K.⁵ Dunn, J.R.⁶ Farley, M.M.⁷ Holzbauer, S.M.⁸ Meek, J.I.⁹ Phipps, E.C.¹⁰ Wilson, L.E.¹¹ Winston, L.G.¹² Cohen, J.A.¹³ Limbago, B.M.¹⁴ Fridkin, S.K.¹⁵ Gerding, D.N.¹⁶ McDonald, L.C.¹⁷

2
- 84922940698
- The epidemiology of clostridium difficile infection inside and outside health care institutions
- Gerding DN, Lessa FC 2015. The epidemiology of Clostridium difficile infection inside and outside health care institutions. Infect Dis Clin North Am 29:37-50. http://dx.doi.org/10.1016/j.idc.2014.11.004.
- (2015) Infect Dis Clin North Am , vol.29 , pp. 37-50
- Gerding, D.N.¹ Lessa, F.C.²

3
- 77951026738
- Clinical practice guidelines for clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)
- Cohen SH, Gerding DN, Johnson S, Kelly C.P., Loo VG, McDonald LC, Pepin J, Wilcox MH 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31:431-455. http://dx.doi.org/10.1086/651706.
- (2010) Infect Control Hosp Epidemiol , vol.31 , pp. 431-455
- Cohen, S.H.¹ Gerding, D.N.² Johnson, S.³ Kelly, C.P.⁴ Loo, V.G.⁵ McDonald, L.C.⁶ Pepin, J.⁷ Wilcox, M.H.⁸

4
- 84875952150
- Guidelines for diagnosis, treatment, and prevention of clostridium difficile infections
- quiz 499
- Surawicz CM, Brandt LJ, Binion D.G., Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland L.V., Mellow M., Zuckerbraun BS. 2013. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108:478-498; quiz 499. http://dx.doi.org/10.1038/ajg.2013.4.
- (2013) Am J Gastroenterol , vol.108 , pp. 478-498
- Surawicz, C.M.¹ Brandt, L.J.² Binion, D.G.³ Ananthakrishnan, A.N.⁴ Curry, S.R.⁵ Gilligan, P.H.⁶ McFarland, L.V.⁷ Mellow, M.⁸ Zuckerbraun, B.S.⁹

5
- 84905057299
- Vancomycin, metronidazole, or tolevamer for clostridium difficile infection: Results from two multinational, randomized, controlled trials
- Johnson S, Louie TJ, Gerding D.N., Cornely OA, Chasan-Taber S, Fitts D, Gelone S.P., Broom C., Davidson DM; Polymer Alternative for CDI Treatment (PACT) investigators. 2014. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 59:345-354. http://dx.doi.org/10.1093/cid/ciu313.
- (2014) Clin Infect Dis , vol.59 , pp. 345-354
- Polymer Alternative for CDI Treatment (PACT) investigators¹ Johnson, S.² Louie, T.J.³ Gerding, D.N.⁴ Cornely, O.A.⁵ Chasan-Taber, S.⁶ Fitts, D.⁷ Gelone, S.P.⁸ Broom, C.⁹ Davidson, D.M.¹⁰

6
- 84859007390
- Fidaxomicin versus vancomycin for infection with clostridium difficile in Europe, Canada, and the USA: A double-blind, non-inferiority, randomised controlled trial
- Cornely OA, Crook DW, Esposito R, Poirier A., Somero MS, Weiss K, Sears P, Gorbach S; OPT-80-004 Clinical Study Group. 2012. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 12:281-289. http://dx.doi.org/10.1016/S1473-3099(11)70374-7.
- (2012) Lancet Infect Dis , vol.12 , pp. 281-289
- Cornely, O.A.¹ Crook, D.W.² Esposito, R.³ Poirier, A.⁴ Somero, M.S.⁵ Weiss, K.⁶ Sears, P.⁷ Gorbach, S.⁸

7
- 79551527297
- Fidaxomicin versus vancomycin for clostridium difficile infection
- Louie TJ, Miller MA, Mullane K.M., Weiss K., Lentnek A, Golan Y, Gorbach S., Sears P, Shue Y-K. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364:422-431. http://dx.doi.org/10.1056/NEJMoa0910812.
- (2011) N Engl J Med , vol.364 , pp. 422-431
- Louie, T.J.¹ Miller, M.A.² Mullane, K.M.³ Weiss, K.⁴ Lentnek, A.⁵ Golan, Y.⁶ Gorbach, S.⁷ Sears, P.⁸ Shue, Y.-K.⁹

8
- 59749103290
- OPT-80 eliminates clostridium difficile and is sparing of bacteroides species during treatment of C. Difficile infection
- Louie TJ, Emery J, Krulicki W., Byrne B, Mah M. 2009. OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 53:261-263. http://dx.doi.org/10.1128/AAC.01443-07.
- (2009) Antimicrob Agents Chemother , vol.53 , pp. 261-263
- Louie, T.J.¹ Emery, J.² Krulicki, W.³ Byrne, B.⁴ Mah, M.⁵

9
- 84867364735
- CMS to compensate hospitals for inpatient use of fidaxomicin, glucarpidase
- Thompson CA. 2012. CMS to compensate hospitals for inpatient use of fidaxomicin, glucarpidase. Am J Health Syst Pharm 69:1618-1619. http://dx.doi.org/10.2146/news120070.
- (2012) Am J Health Syst Pharm , vol.69 , pp. 1618-1619
- Thompson, C.A.¹

10
- 55249105923
- Clostridium difficile - More difficult than ever
- Kelly CP, LaMont JT 2008. Clostridium difficile - more difficult than ever. N Engl J Med 359:1932-1940. http://dx.doi.org/10.1056/NEJMra0707500.
- (2008) N Engl J Med , vol.359 , pp. 1932-1940
- Kelly, C.P.¹ LaMont, J.T.²

11
- 0036311186
- Breaking the cycle: Treatment strategies for 163 casesofrecurrent clostridium difficile disease
- McFarland LV, Elmer GW, Surawicz CM 2002. Breaking the cycle: treatment strategies for 163 casesofrecurrent Clostridium difficile disease. Am J Gastroenterol 97:1769-1775. http://dx.doi.org/10.1111/j.1572-0241.2002.05839.x.
- (2002) Am J Gastroenterol , vol.97 , pp. 1769-1775
- McFarland, L.V.¹ Elmer, G.W.² Surawicz, C.M.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.